BIOPHARMA CREDIT PLC

Report Publication Announcement • Mar 1, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3046G

BioPharma Credit PLC

01 March 2018

1 March 2018

BIOPHARMA CREDIT PLC

("The Company")

NOTICE OF RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2017, on Thursday 8 March 2018.

A management presentation will be held at 09:30 at Buchanan, 107 Cheapside, EC2V 6DN. A conference call facility will also be available.

To confirm your attendance, or request conference call details, RSVP to henryw@buchanan.uk.com.

LEI: 213800AV55PYXAS7SY24

-Ends-

Enquiries

BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

Goldman Sachs International (Joint Bookrunner)

+44 (0)207 774 1000

Charlie Lytle

Shomick Bhattacharya / Jennie Holloway / Tom Hartley

J.P. Morgan Cazenove (Joint Bookrunner)

+44 (0)20 7742 4000

William Simmonds / Oliver Kenyon / Anne Ross

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORZMGZZNRVGRZM